Jason Wild
Founder, President & Chief Investment Officer @ JW Asset Management
Bedford, United States
Jason Wild is a Series A investor at JW Asset Management in Bedford focused on Medical and Cannabis. Jason Wild is the Founder, President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceuticalsector. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jason Wild invests in
Stages Jason Wild invests in
Countries Jason Wild invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 3 (38%)
- Cannabis 3 (38%)
- Pharmaceutical 3 (38%)
- Health Care 2 (25%)
- SaaS 1 (13%)
Stage
- Series A 2 (25%)
- Venture - Series Unknown 2 (25%)
- Pre-Seed 1 (13%)
- Series C 1 (13%)
- Post-IPO Debt 1 (13%)
Country
- United States 6 (75%)
- Canada 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TerrAscend is a vertically-integrated Canadian cannabis company that strives to create and deliver quality products and services that meet the evolving needs of the cannabis market. It provides support to patients through its wholly-owned subsidiaries, Solace Health Inc., a licensed producer of cannabis under the Access to Cannabis for MedicalPurposes Regulations, and Terra Health Network Inc., a provider of clinical support and education programs led by health care professionals. TerrAscend offers prescription cannabinoids and medical cannabis solutions for patients suffering from chronic pain and debilitating illnesses and focuses on drug research and development, cannabis devices, delivery systems, and hemp health products. | $57.7M / Post-IPO Debt / Jul 09, 2025 | ||
| Named a Top 10 "Most Innovative Workplace” solution of 2024 by Fast Company, InnovationForce democratizes innovation with AI-powered solutions that enable ecosystem collaboration and corporate level decision-making to simplify innovation. Our customers make decision 85% faster saving on average $500,000 per idea. By leveraging the “collectivegenius” of crowds and insights from our co-founder, renowned Harvard Business School professor Dr. Linda Hill, the platform has proven it can help leaders solve critical climate and infrastructure challenges faster and smarter. | Pre-Seed / Mar 26, 2024 | ||
| Tyson 2.0 is a cannabis company producing cannabis products known for purity, precision, and wide accessibility. Providing consumers an outstanding selection of products, Tyson 2.0 is an extraordinary balance of premium and affordable, full-spectrum cannabis flower, concentrates, and consumables available at retailers nationwide. The company wasformed by the legendary boxer, entrepreneur, and icon, Mike Tyson. | $9M / Series A / Jun 30, 2022 | ||
| Gage Cannabis Co. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. | $10M / Venture - Series Unknown / Dec 16, 2020 | ||
| Vitruvias Therapeutics is a start-up generic pharmaceutical company that will focus on developing niche topical generic products that are sold only by prescription. The name of the company is taken from Leonardo da Vinci’s drawing “The Vitruvian Man” which refers to the idealized proportionality of the human figure.The company was founded in 2013and is based in Montgomery, Alabama. | $11.5M / Series A / Jan 05, 2018 | ||
| Vensun Pharmaceuticals is a pharmaceutical company developing generic prescription products in various dosage forms. As a rapidly emerging generic pharmaceutical company, Vensun has filed several Abbreviated New Drug Applications (ANDAs) with the FDA through its partnerships and currently has over 30 products in active development. We are activelyseeking additional opportunities for partnerships, strategic alliances, and product acquisitions to enhance our existing development portfolio. | $22.5M / Series C / Dec 01, 2016 | ||
| Establishment Labs is a medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to thestrictest quality assurance testing throughout the manufacturing process. Motiva Implants are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards. | $15M / Debt Financing / Sep 29, 2016 | ||
| Establishment Labs is a medical technology company with a strong emphasis on innovation that designs, develops, manufactures and markets an innovative product portfolio. Its CE-marked Motiva Implants® line of silicone breast implants (http://www.motivaimplants.com) utilizes ultra-high purity medical-grade silicone and is subject to thestrictest quality assurance testing throughout the manufacturing process. Motiva Implants are sold in more than 60 countries worldwide. Puregraft®’s FDA cleared and CE-Marked technology provides plastic surgeons with purified fat for reinjection on the sterile field and is used in hospitals and clinics around the world. Divina® is a proprietary 3D imaging technology for full integration in consultation and surgical planning of unique solutions for breast aesthetics and reconstruction. All manufacturing facilities are fully compliant with both FDA and ISO applicable standards. | $6.8M / Venture - Series Unknown / Jul 20, 2016 |
Co-Investors
About JW Asset Management
JW Asset Management is a New York-based investment firm that primarily invests within the healthcare sector. The company runs 3 Hedge Funds and two Private Equity Funds. It has led the investor group in the 2010 acquisition of Arbor Pharmaceuticals, Inc. and recently as the lead investor in TerrAscend Corp.
JW Asset Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jason Wild
Founder, President & Chief Investment Officer
|
|||
Jason Klarreich
Managing Director, CFO, COO, & CCO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jason Wild invest in?
Jason Wild invests primarily in Medical, Cannabis and Pharmaceutical startups, most often at Series A and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jason Wild?
Public channels for Jason Wild include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jason Wild last invest?
The most recent investment recorded for Jason Wild closed in Jul 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
